Double Digit NASDAQ Stock Winners: IPHA, DPRO, APOP
8:05 am Tuesday, September 07th, 2021
Following are major stock gainers on Nasdaq in Friday’s trading session:
Innate Pharma S.A. (NASDAQ:IPHA) was the active stock gainer on Friday and soared 47% to $6.15 after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress.
The presentations include a late-breaker abstract on a Phase 2 trial highlighting the progression-free survival data for monalizumab combination therapy in non-small cell lung cancer (NSCLC). Analyst Daina Graybosch says that a positive outcome would de-risk a vast opportunity for monalizumab and transform the narrative around the Company.
Draganfly Inc. (NASDAQ:DPRO) was another notable winner as the stock went up 24% to end the session at $3.81 after the company announced today that it is expanding its partnership with Alabama State University (“ASU”), upgrading its Vital Intelligence Smart Vital Assessment Stations, and delivering its patented drone technology Varigard sanitizing spray for ASU’s annual Labor Day Classic football game.
ASU made history last year by becoming the first university in the United States to implement Draganfly’s safety system as part of the Safely Opening Schools Program, which provides an integrated health and screening protocol to be used campus-wide to screen, detect, assess, protect, and provide continuous action against the potential threat of infectious diseases, including COVID-19.
Cellect Biotechnology Ltd. (NASDAQ:APOP) moved up 22% to $6.69 after the company announced the first ApoGraftTM transplantation in a Leukemia patient in the Company’s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company’s cell selection technology designed to optimize immune therapy, in this application – prevent graft-versus-host disease (GVHD) following bone marrow transplantation.
Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that is acquiring Cellect’s proprietary technology concurrently with such merger.
